SILEXION THERAPEUTICS CORP (SLXN) Forecast, Price Target & Analyst Ratings

NASDAQ:SLXN • KYG1281K1307

Current stock price

1.05 USD
+0.06 (+6.06%)
Last:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for SILEXION THERAPEUTICS CORP (SLXN).

Forecast Snapshot

Consensus Price Target

Price Target
$6.12
+ 482.86% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
N/A
Period
Q1 / 2026
EPS Estimate
-$1.32
Revenue Estimate
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
82.50%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$6.12
Upside
+ 482.86%
From current price of $1.05 to mean target of $6.12, Based on 8 analyst forecasts
Low
$6.06
Median
$6.12
High
$6.30

Price Target Revisions

1 Month
-33.33%
3 Months
-33.33%

Price Target Summary

8 Wall Street analysts provided a forecast for the next 12 months for SLXN. The average price target is 6.12 USD. This implies a price increase of 482.86% is expected in the next year compared to the current price of 1.05.
The average price target has been revised downward by 33.33% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

SLXN Current Analyst RatingSLXN Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 1 2 3 4

Analyst Ratings History

SLXN Historical Analyst RatingsSLXN Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -16 -14 -12 -10 -8 -6 -4 -2 0 2 4 6

Analyst Ratings Consensus

ChartMill Buy Consensus
82.50%
SLXN was analyzed by 8 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about SLXN.
In the previous month the buy percentage consensus was at a similar level.
SLXN was analyzed by 8 analysts. More opinions would make the average more meaningful.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2025-12-15Litchfield HillsInitiate Buy
2025-03-20Maxim GroupMaintains Buy -> Buy
2024-11-01Maxim GroupInitiate Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
N/A
Period
Q1 / 2026
EPS Estimate
-$1.32
Revenue Estimate
N/A
Revenue Q2Q
N/A
EPS Q2Q
66.26%
Number of Analysts
3

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A

Next Earnings Summary

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2029

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
Revenue
YoY % growth
SLXN revenue by date.SLXN revenue by date.
N/AN/AN/AN/A
EBITDA
YoY % growth
SLXN ebitda by date.SLXN ebitda by date.
N/AN/AN/A-6M-12.546M
-109.09%		-11.618M
7.40%		N/AN/AN/AN/A
EBIT
YoY % growth
SLXN ebit by date.SLXN ebit by date.
-200K-770K
-285.00%		-1.11M
-44.16%		-6.045M
-444.63%		-12.571M
-107.94%		-11.632M
7.47%		N/A
-25.37%		N/A
-20.75%		N/A
-22.32%		N/A
Operating Margin
SLXN operating margin by date.SLXN operating margin by date.
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
EPS
YoY % growth
SLXN eps by date.SLXN eps by date.
N/AN/AN/AN/AN/A-12.50
92.76%		N/A
66.38%		N/A
45.87%		N/A
-19.73%		N/A
-109.74%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26
EPS
Q2Q % growth		-1.32
66.26%		-1.34
69.07%		-1.36
52.90%		-0.51
63.57%
Revenue
Q2Q % growth		N/AN/AN/AN/A
EBITDA
Q2Q % growth		N/AN/AN/AN/A
EBIT
Q2Q % growth		-4.161M
-152.16%		-4.233M
-85.33%		-4.306M
-30.82%		-4.382M
0.55%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

SLXN Yearly EPS VS EstimatesSLXN Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 -50 -100 -150

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
21.24%
EPS Next 5 Year
11.45%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

SILEXION THERAPEUTICS CORP / SLXN Forecast FAQ

What is the average price target for SILEXION THERAPEUTICS CORP (SLXN) stock?

8 analysts have analysed SLXN and the average price target is 6.12 USD. This implies a price increase of 482.86% is expected in the next year compared to the current price of 1.05.

What is the consensus rating for SLXN stock?

The consensus rating for SILEXION THERAPEUTICS CORP (SLXN) is 82.5 / 100 . This indicates that analysts generally have a positive outlook on the stock.